7,405.25

+3.25

+0.04%

51,521.00

+136.00

+0.26%

27,035.25

-50.00

-0.18%

Russell 2000 Futures

2,764.80

+4.30

+0.16%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,071.00

-3.90

-0.10%

74,732.02

-1,021.93

-1.35%

Crude Oil Dec 26

90.44

-0.39

-0.43%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Delayed Quote USD

BeyondSpring Inc. (BYSI)

0.6260 -0.0064 (-1.01%)

At close: November 6 at 4:00:01 PM EST

Loading Chart for BYSI

Chart Range Bar

Interval:

In partnership with ChartIQ

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances

BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances

BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)

BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)

Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Mobilize your Website

View Site in Mobile | Classic

Share by: